Signs Memorandum of Understanding with Attwill

25 июн. 2020 г.

Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP

Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year
Through Large Scale Lyophilization, Tableting and Coating

establish AMS as a resource for lyophilization development and large scale manufacturing including tableting and enteric coating for Vaxart’s oral COVID-19 vaccine.

AMS will be assigning dedicated resources and equipment for the scale up and commercial production of the vaccine upon entering a formal agreement.

investors.vaxart.com/news-releases/news-release-details/vaxart-inc-signs-memorandum-understanding-attwill-medical

27 июн. 2020 г.

Сделка активна

Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed

today announced that its oral COVID-19 vaccine has been selected to participate in a non-human primate (NHP) challenge study, organized and funded by Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021.

The study is designed to demonstrate the efficacy of Vaxart’s oral COVID-19 vaccine candidate.

finance.yahoo.com/news/vaxart-covid-19-vaccine-selected-120010175.html